Experimental Alzheimer's drug ELND005, at its mid-stage clinical trial, causes 9 deaths, forcing the pharma companies involved to drop the medicine all together. A product of Elan Corp and Transition Therapeutics Inc., the drug was soon to be launched in the markets. But doubts have been raised on this issue now.

The shares of both are being affected after this incident where Transition Therapeutics Inc. saw an all time low situation since 2002, and a fall of 2.3% was recorded by Elan shares.